FDA delays Dupixent in COPD decision by three months while EMA gives thumbs-up
Sanofi and Regeneron will have to wait three more months for a major FDA decision on expanding Dupixent’s label, the companies disclosed Friday morning. Meanwhile …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.